EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access

Transcatheter aortic valve implantation in pure aortic regurgitation: one-year outcomes of the AURORA trial

Fei-Cheng Yu, Xiao-Ping Peng, Jing Yao, Yun-Feng Yan, Silvia Corona, Bo Fu, Sheng Wang, Hai-Ping Wang, Xi-Jin Zhuang, Zheng-Ming Jiang, Yue-Wu Zhao, Yi-Da Tang und 11 weitere

EuroIntervention · 2025-08 · 21 (16) · 952-960

DOI: 10.4244/eij-d-25-00224 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift EuroIntervention, 2025-08. Verfasst von Fei-Cheng Yu und 22 weiteren Autor:innen. Beteiligte Einrichtung: Sir Run Run Shaw Hospital (SRRSH), affiliated with the Zhejiang University School of Medicine, Hangzhou, China. Hauptthemen laut MEDLINE: Transcatheter Aortic Valve Replacement, Aortic Valve Insufficiency, Aortic Valve. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 19 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Transcatheter aortic valve implantation (TAVI) in pure aortic regurgitation (AR) remains challenging because of inadequate anchoring forces. Traditional approaches, which rely solely on virtual annulus oversizing, have demonstrated limited success. We propose a novel anatomical classification system and dual-anchoring theory to optimise the TAVI strategy in patients with pure AR. AIMS: We aimed to evaluate the efficacy and safety of TAVI in pure AR using a novel anatomical classification system and dual-anchoring theory. METHODS: The AURORA trial is a prospective, multicentre, single-arm study conducted across 16 centres in China. Patients with severe pure AR underwent comprehensive anatomical assessment using multidetector computed tomography (CT). Based on the ability to provide adequate anchoring forces (≥10% of oversizing) in three zones (left ventricular outflow tract, anatomical annulus, and ascending aorta), patients were classified into 4 types. Those with anatomical types 1-3 were enrolled and underwent TAVI using the VitaFlow valve system. The primary efficacy endpoint was device success, and the primary safety endpoints included 30-day mortality and major complications. RESULTS: Among 187 screened patients, 100 patients with suitable anatomy (types 1-3) were enrolled. The mean age was 72.7±7.2 years, and the mean Society of Thoracic Surgeons Predicted Risk of Mortality score was 9.10±5.81%. Device success was achieved in 91% of cases, with no procedural mortality. The new permanent pacemaker implantation rate was 9%. Postprocedural CT analysis in 43 patients revealed that the maximum contact forces were primarily localised between the virtual annulus and the sinotubular junction (83.7% of cases). No device failure occurred in later cases. CONCLUSIONS: The AURORA classification system shows that comprehensive anatomical assessment can lead to favourable outcomes in pure AR using conventional TAVI devices. The low pacemaker implantation rate and the absence of device failure in later cases suggest that optimal anatomical matching may be superior to aggressive oversizing strategies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Transcatheter Aortic Valve ReplacementAortic Valve InsufficiencyAortic ValveHumansFemaleMaleAgedTreatment OutcomeProspective StudiesAged, 80 and overMultidetector Computed TomographyHeart Valve ProsthesisChina

Autor:innen und Institutionen

  • Sir Run Run Shaw Hospital (SRRSH), affiliated with the Zhejiang University School of Medicine, Hangzhou, China.
  • Department of Cardiology, The First Affiliated Hospital of Nanchang University, Nanchang, China.
  • Interventional Center of Valvular Heart Disease, Beijing Anzhen Hospital, Capital Medical University, Beijing, China.
  • Montreal Heart Institute, Montreal, Canada.
  • Tianjin Chest Hospital, Tianjin, China.
  • Fuwai Central China Cardiovascular Hospital, Zhengzhou, China.

Zitieren

APA

Yu, F. C., Peng, X. P., Yao, J., Yan, Y. F., Corona, S., Fu, B., Wang, S., Wang, H. P., Zhuang, X. J., Jiang, Z. M., Zhao, Y. W., Tang, Y. D., Xu, J. Z., Li, C. B., Chen, H., Han, K., Huang, H., Guo, L., Ben Ali, W., …, & Song, G. Y. (2025). Transcatheter aortic valve implantation in pure aortic regurgitation: one-year outcomes of the AURORA trial. EuroIntervention, 21(16), 952-960. https://doi.org/10.4244/eij-d-25-00224

Vancouver

Yu FC, Peng XP, Yao J, Yan YF, Corona S, Fu B, et al. Transcatheter aortic valve implantation in pure aortic regurgitation: one-year outcomes of the AURORA trial. EuroIntervention. 2025;21(16):952-960. doi:10.4244/eij-d-25-00224

BibTeX
@article{Yu2025,
  author = {Yu, Fei-Cheng and Peng, Xiao-Ping and Yao, Jing and Yan, Yun-Feng and Corona, Silvia and Fu, Bo and Wang, Sheng and Wang, Hai-Ping and Zhuang, Xi-Jin and Jiang, Zheng-Ming and Zhao, Yue-Wu and Tang, Yi-Da and Xu, Ji-Zhe and Li, Chuan-Bao and Chen, Hui and Han, Ke and Huang, Hui and Guo, Liang and Ben Ali, Walid and Modine, Thomas and Jilaihawi, Hasan and Piazza, Nicolo and Song, Guang-Yuan},
  title = {Transcatheter aortic valve implantation in pure aortic regurgitation: one-year outcomes of the AURORA trial},
  journal = {EuroIntervention},
  year = {2025},
  volume = {21},
  number = {16},
  pages = {952--960},
  doi = {10.4244/eij-d-25-00224}
}
Kostenlos starten →